Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | NCF1 | P14598 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5132193 | 0.82 | LMNA (0.51) | IGF1RLMNATSHRTP53GAA | |
| SCHEMBL6334528 | 0.82 | LMNA (0.51) | IGF1RLMNATSHRTP53GAA | |
| SCHEMBL4834067 | 0.77 | NCF1 (0.53) | IGF1RLMNATSHRTP53GAA | |
| SCHEMBL5131872 | 0.74 | IGF1R (0.56) | IGF1RHTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL4742006 | 0.70 | TSHR (0.67) | LMNATSHRL3MBTL1HTTMEN1 | |
| SCHEMBL6333180 | 0.69 | L3MBTL1 (0.53) | LMNATSHRTP53GAAL3MBTL1 | |
| SCHEMBL14588014 | 0.67 | EHMT2 (0.55) | IGF1RLMNATP53L3MBTL1HTT | |
| SCHEMBL15101603 | 0.67 | LMNA (0.73) | LMNATSHRTP53GAAL3MBTL1 | |
| SCHEMBL31673809 | 0.67 | LMNA (0.73) | LMNATSHRTP53GAAL3MBTL1 | |
| SCHEMBL2563976 | 0.67 | IGF1R (1.00) | IGF1RLMNATSHRTP53GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050054850-A1 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | ENCYSIVE PHARMACEUTICALS INC. | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054850-A1 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | UTS2R, GPR17, NTSR2 | IGF1R 2956/4885LMNA 3004/4885TSHR 1103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.